A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma

Inclusion Criteria:

1. Histologically confirmed carcinoma or carcinosarcoma of the endometrium with evidence of persistent disease or progression after initial surgery and adjuvant chemotherapy, radiotherapy, or both, not amenable for curative salvage therapy.
2. ErbB2 gene amplification by FISH (ErbB2 gene copies to chromosome 17 signals) of \> = 2.0; ErbB2 overexpression is defined by immunostaining \>=2 for ErB2
3. Measurable disease, defined as ≥1 lesions that can be accurately measured in

   * 1 dimensions as ≥20 mm by conventional techniques OR as ≥10 mm by spiral CT scan, MRI or PET scan (those who undergo cytoreductive salvage surgery with residual tumor ≥ 20 mm are eligible)
4. Those who are chemotherapy-naive be enrolled until failing one chemotherapy regimen
5. Prior treatments with radiation therapy for palliative management of metastatic disease is permitted provided that at least 4 weeks have elapsed since the last fraction of radiation therapy, disease progression has been documented and all treatment related adverse events are ≦ grade 2 at the time of registration.
6. Life expectancy ≥ 12 weeks
7. ECOG(Eastern Cooperative Oncology Group) performance status 0-2
8. Patients must have normal organ and marrow function measured within 14 days

Exclusion Criteria:

1. Previously unirradiated, isolated vaginal, pelvic or paraaortic lymph node, lung (which confined to one lobe that can be resected or radiated) recurrence or other potentially curable recurrence such as central pelvic recurrence for which a pelvic exenteration is feasible
2. Pregnant or lactating women.
3. Subjects who have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment)
4. Prior therapy with Lapatinib or Ixabepilone.
5. CNS metastases.
6. Ongoing other concurrent investigational agents or anticancer therapy
7. Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, serious non- healing wound/ulcer/bone fracture, or psychiatric illness/social situations that would limit compliance with study requirements.
8. Patients with GI tract disease resulting in an inability to take oral medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis).
9. Preexisting peripheral neuropathy≥G2